INTRODUCTION
Hyperpigmentation disorders such as melasma, post-inflammatory hyperpigmentation, solar lentigines, and drug-induced pigmentation are common dermatologic complaints, particularly in patients with skin of color. These conditions can have significant psychosocial impacts, such as decreased quality of life and low self-esteem. The mainstay of treatment has historically been topical depigmenting agents, with hydroquinone considered to be the gold standard due to its potent efficacy.1,2
However, recent years have seen a rise in safety concerns, regulatory scrutiny, and patient hesitancy regarding hydroquinone use. Known potential adverse effects such as exogenous ochronosis and reports suggesting carcinogenicity in animal studies have fueled concerns.3,4 This has led to a shift in the therapeutic landscape, prompting increased interest in combination regimens like short-term triple combination therapy (TCT) and alternative agents such as niacinamide, kojic acid, azelaic acid, arbutin, and thiamidol.
This review aims to provide a comprehensive overview of hydroquinone's clinical utility, mechanism of action, safety profile, and global regulatory history. In addition, we explore commonly prescribed combination therapies and evaluate the evidence supporting alternative depigmenting agents, culminating in an updated framework for clinical decision-making in pigmentary disorders.
Hydroquinone
Mechanism, Clinical Use, and Safety Considerations Hydroquinone is a reversible inhibitor of tyrosinase, the rate-limiting enzyme in melanin synthesis, and also promotes degradation of melanosomes and melanocytes, leading to skin lightening.1,5 It is widely used for the treatment of melasma, solar lentigines, freckles, and post-inflammatory hyperpigmentation.4,5
The most common acute adverse effect is irritant or allergic contact dermatitis, with post-inflammatory pigmentary change and hypopigmentation also reported.1,4,5 A rare effect is trimethylaminuria, producing a fish-like odor in sweat, urine, and saliva.5 Chronic adverse events include nail discoloration, conjunctival melanosis, corneal degeneration, and, most notably, exogenous ochronosis, a gray-blue discoloration associated with high concentrations or treatment durations >1 year, often affecting the cheeks, nose, temples, and neck.4,6
To minimize risk, hydroquinone is typically limited to concentrations ≤4%, applied once or twice daily for 2–6 months, with discontinuation if no improvement is observed after 2 months.3,5 Treatment holidays and concomitant sunscreen use are recommended to reduce photodamage-related recurrence.3,5 Application should be confined to affected areas, as use on uninvolved skin may cause hypopigmentation. Rarely, distant depigmentation (leukoderma) can occur, particularly in patients of African descent; in such cases, hydroquinone should be stopped immediately and oral corticosteroids considered.2,5
However, recent years have seen a rise in safety concerns, regulatory scrutiny, and patient hesitancy regarding hydroquinone use. Known potential adverse effects such as exogenous ochronosis and reports suggesting carcinogenicity in animal studies have fueled concerns.3,4 This has led to a shift in the therapeutic landscape, prompting increased interest in combination regimens like short-term triple combination therapy (TCT) and alternative agents such as niacinamide, kojic acid, azelaic acid, arbutin, and thiamidol.
This review aims to provide a comprehensive overview of hydroquinone's clinical utility, mechanism of action, safety profile, and global regulatory history. In addition, we explore commonly prescribed combination therapies and evaluate the evidence supporting alternative depigmenting agents, culminating in an updated framework for clinical decision-making in pigmentary disorders.
Hydroquinone
Mechanism, Clinical Use, and Safety Considerations Hydroquinone is a reversible inhibitor of tyrosinase, the rate-limiting enzyme in melanin synthesis, and also promotes degradation of melanosomes and melanocytes, leading to skin lightening.1,5 It is widely used for the treatment of melasma, solar lentigines, freckles, and post-inflammatory hyperpigmentation.4,5
The most common acute adverse effect is irritant or allergic contact dermatitis, with post-inflammatory pigmentary change and hypopigmentation also reported.1,4,5 A rare effect is trimethylaminuria, producing a fish-like odor in sweat, urine, and saliva.5 Chronic adverse events include nail discoloration, conjunctival melanosis, corneal degeneration, and, most notably, exogenous ochronosis, a gray-blue discoloration associated with high concentrations or treatment durations >1 year, often affecting the cheeks, nose, temples, and neck.4,6
To minimize risk, hydroquinone is typically limited to concentrations ≤4%, applied once or twice daily for 2–6 months, with discontinuation if no improvement is observed after 2 months.3,5 Treatment holidays and concomitant sunscreen use are recommended to reduce photodamage-related recurrence.3,5 Application should be confined to affected areas, as use on uninvolved skin may cause hypopigmentation. Rarely, distant depigmentation (leukoderma) can occur, particularly in patients of African descent; in such cases, hydroquinone should be stopped immediately and oral corticosteroids considered.2,5
